Bacillus Calmette-Guérin Failures and Beyond: Contemporary Management of Non-Muscle-Invasive Bladder Cancer

Reviews in Urology

Thomas E Keane¹  Michael A O’Donnell¹  Michael S Cookson¹  Richard E Greenberg¹  H. Barton Grossman¹ 

[1] *Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

关键词: Bladder cancer;    Bacillus Calmette-Guérin;    Cystectomy;    Gemcitabine;    Valrubicin;   

DOI  :  

学科分类：基础医学

来源: MedReviews, LLC

【 摘 要 】

In the United States, bacillus Calmette-Guérin (BCG) is the treatment most used for superficial bladder cancer. Patients with carcinoma in situ (CIS) treated with intravesical BCG plus interferon have a 60% to 70% chance of a complete and durable response if they were never treated with BCG or if they failed only 1 prior induction or relapsed more than a year from induction. Intravesical gemcitabine is safe, but its usefulness for BCG-refractory patients is unclear. Valrubicin, approved for intravesical treatment of BCG-refractory CIS of the bladder, has efficacy and acceptable toxicity. Cystectomy should be considered in high-risk, non-muscle-invasive cancer, particularly if intravesical therapy failed.

【 授权许可】

Unknown